Small Cap Feast
Small Cap Feast – 15th September 2016
Dish of the Day:
No primary today
No primary today
Off the Menu:
Following the disposal of its trading operations Cdialogues (CDOG) is to leave AIM
Following the disposal of its trading operations Cdialogues (CDOG) is to leave AIM
What’s Cooking in the IPO Kitchen?
Biffa — Press reports that the waste disposal company will shortly unveil plans to raise up to £300m in a London IPO.
PureGym — The UK’s largest gym operator is seeking a main market listing and seeks to raise £190m primarily to pay down debt.
Misys — The press reports that the Banking Technology provider owned by Vista Equity Partners is seeking a £5.5bn float in London.
Bacanora Lithium — To list on AIM around 28 Sep as holding company for TSX listed Bacanora Minerals at £100m market cap.
Collagen Solutions (COS.L) 1.13p £5.9m
The developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, has been invited to participate as an industrial collaborator for an upcoming Horizon 2020 project. The wholly grant-funded project addresses a pressing clinical need using cell-based tissue regeneration techniques. The project should begin in early 2017 for approximately five years, over which Collagen Solutions will receive approximately €500,000 of EU funding.
Medaphor Group (MED.L) 31p £9.89m
The global provider of advanced ultrasound skills training simulators for medical professionals, announced that ScanTrainer Professional, ultrasound skills training simulator, has been awarded official Accredited Provider status by The CPD Standards Office. This means doctors and sonographers in several territories can gain CPD points by completing ScanTrainer’s curriculum-based general medicine, obstetrics, gynaecology and emergency medicine ultrasound modules.
Powerflute (Powr.L) 73.75p £214.35m
The paper and packaging group has announced the terms of a recommended cash offer to be made by Nordic Packaging and Container (Finland) Holdings. 90p in cash per share and 90p in cash less the applicable subscription price for each option. 27.5% held by the Chairman Dermot Smurfit and associates has been agreed at the lower price of 80p. The 90p price is a premium of circa 22% to yesterday’s close.
Crawshaw Group (CRAW.L) 73.5p £58m
Further to the June AGM statement that had noted suppressed footfall due to international football, bad weather and Brexit, the fresh meat and food-to-go retailer has stated that these factors persisted through to the end of H1, resulting in a further reduction in like for like sales, although this was partly mitigated again by a further strengthening of gross margin. Conditions remain difficult. Confident of restoring sales momentum for key winter season. FyJan17E consensus £50.3m sales and £170k pre-tax loss.
Tribal Group (TRB.L) 55.5p £108.4m
The provider of products, services and software to the international higher education, further education, training and vocational learning markets has announced June interims in line with expectations with FY guidance unchanged. Revenue down 22% to £45.2m. Operating profit down 81% to £0.5m. Profits expected to be H2 weighted. Management team refreshed. Annualised cost savings by year end of £8.5m. Recurring revs 38%. FY Consensus looks for £89.4m revenues & £2.31m PBT.
Franchise Brands (FRAN.L) 41p £19.32m
Recently listed multi-brand international franchisor, has announced H1Jun16 results. Total revenue up 10% to £2.5m. PBT up 18.3% £724k. ChipsAway and Ovenclean, the Group’s two main brands, continue to trade well. No discernible Brexit effect on franchisee recruitment or trading. Strong pipeline of acquisition prospects. Y/e cash of £1.16m with £2.9m net raised thereafter in August IPO. There are no forecasts in the market.
Cronin Group (CRON.L) 1.13p £5.91m
The specialist in the digitisation of chemical space coupled with innovative chemical drug discovery announced H1Jun16 results. Zero revenues and a reduced loss of £0.31m. Substantive progress in further developing the Company’s strategic roadmap to digitise chemistry. In the period Steve Coles joined the Company from main list Mears Group plc as Chief Technology Officer. Cash and short term deposits at 30 June 2016 of £5.10 million.
Purplebricks Group (PURP.L) 130p £318.6m
AGM Trading update from the hybrid estate agency. Trading since the start of the new financial year on 1 May has been very encouraging, with little discernible impact following the EU referendum. For the period, UK instructions are up 121% YoY and have continued to grow culminating in 3,156 instructions in August. Market share versus online peers has strengthened to 65%. On track to meet FY expectations with UK to move into profitability. FYAPR17E revs £43.2m, £1.8m pre-tax loss.
Colefax Group (CFX.L) 497.5p £45.99m
The international designer and distributor of luxury furnishing fabrics & wallpapers has updated on trading. Conditions have remained relatively challenging in all major markets. In the core Fabric Division, sales for the four months to 31 August are up 4% in reported currency but down 7% on a constant currency basis. Broadly in line with expectations. New show rooms in the US and a relocation of the decorating division provide some room for optimism. FYAPR17 PE of 16.9x.
Infrastructure India (IIP.L) 12.13p £82.5m
The infrastructure fund investing directly into assets in India, has entered into a revised management and valuation and portfolio services agreement with Franklin Park Management, the Company’s existing asset manager, to effect a reduction in annual cash fees payable. This will be a fixed feed of £5.5m plus annual issuance of 605.7k shares. Last reported NAV was £325.8m.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email firstname.lastname@example.org with “unsubscribe me”.